Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
Yao-Chun HsuMing-Lun YehGrace Lai-Hung WongChien-Hung ChenCheng-Yuan PengMaria ButiMasaru EnomotoQing XieHuy TrinhCarmen PredaLi LiuKa-Shing CheungYee Hui YeoJoseph HoangChung-Feng HuangMar Riveiro-BarcielaRitsuzo KozukaDoina IstratescuPei-Chien TsaiElena Vargas AccarinoDong-Hyun LeeJia-Ling WuJee Fu HuangChia-Yen DaiRamsey CheungWan-Long ChuangMan-Fung YuenVincent Wai-Sun WongMing-Lung YuMindie H NguyenPublished in: The Journal of infectious diseases (2022)
HBsAg seroclearance rarely occurs in patients with chronic hepatitis B treated with ETV or TDF and is associated with low-level viremia, alanine aminotransferase flare, bilirubin level, and fatty liver.Functional cure of hepatitis B virus infection rarely occurred at an average annual rate of 0.22% during first-line oral antiviral treatment, with higher chances observed in patients with low-level viremia, high-level aminotransferase flare, elevation of serum bilirubin, and fatty liver.